Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 17, 2023 14:57 ET | Source: Spherix Global Insights

Another Medicine to Stop Migraine in its Tracks – Zavzpret™ is Now Available, but Where will Neurologists use it?

Exton, Pennsylvania, Aug. 17, 2023 (GLOBE NEWSWIRE) -- In February 2023, Pfizer published their positive Phase 3 clinical trial results for zavegepant (new brand name, Zavzpret™). At the time,...
August 15, 2023 15:40 ET | Source: Spherix Global Insights

An Old Dog with a New Trick… Ellodi’s APT-1011 Promises EoE Patients a Convenient and Potent Treatment Alternative

Exton, Pennsylvania, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Since launching in May 2022, Sanofi/Regeneron’s Dupixent has been well received by gastroenterologists and allergists as an advancement for...
August 10, 2023 15:15 ET | Source: Spherix Global Insights

What’s on Your Must-Read List? If You Work in Pharma, Add Spherix Global Insights’ Generalized Myasthenia Gravis Patient Chart Audit to that List

Exton, Pennsylvania, Aug. 10, 2023 (GLOBE NEWSWIRE) -- In one of the largest patient-focused studies ever conducted in gMG, Spherix’s RealWorld Dynamix™: Treatment Patterns in generalized Myasthenia...
August 02, 2023 11:15 ET | Source: Spherix Global Insights

How High Is the Bar for Future ALS Treatments? Although Neurologists Express Frustration with Current Treatments, They Are Quick to Adopt Therapies that Promise to Delay ALS Progression

Exton, Pennsylvania, Aug. 02, 2023 (GLOBE NEWSWIRE) -- A quiet but significant advance was made during the last year: not one, but two medicines were FDA approved to delay disease progression in the...
August 01, 2023 12:02 ET | Source: Spherix Global Insights

Breaking Into a Saturated Relapsing Remitting Multiple Sclerosis Market: Where Should Developers Focus?

Exton, Pennsylvania, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Despite outward appearances of being a stagnant market, the relapsing remitting multiple sclerosis (RMS) market continues to offer drug...
July 28, 2023 12:26 ET | Source: Spherix Global Insights

First-to-Market Edge for Apellis’s Syfovre in Geographic Atrophy Diminished in the Face of an Unexpected Safety Signal

Exton, Pennsylvania, July 28, 2023 (GLOBE NEWSWIRE) -- For many who have been following the retina market, the news about the emerging safety signal associated with Apellis’ Syfovre in geographic...
July 27, 2023 16:00 ET | Source: Spherix Global Insights

Market Access Issues Hindering Specialists’ Use of Advanced Systemics in Lupus Nephritis

Exton, Pennsylvania, July 27, 2023 (GLOBE NEWSWIRE) -- While the approvals of GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have provided rheumatologists and nephrologists with...
July 20, 2023 15:07 ET | Source: Spherix Global Insights

Akebia’s Vafseo (vadadustat) Poised to Make Waves for GSK’s Jesduvroq and FibroGen/Astellas’ Evrenzo

Exton, Pennsylvania, July 20, 2023 (GLOBE NEWSWIRE) -- Nephrologists have long awaited the approval of HIF-PH inhibitors for the treatment of anemia in their chronic kidney disease (CKD) patients....
July 18, 2023 09:29 ET | Source: Spherix Global Insights

A Call for Help from Physician Specialists on the Frontline Treating MASLD/MASH

Exton, Pennsylvania, July 18, 2023 (GLOBE NEWSWIRE) -- Data from the Centers for Disease Control & Prevention (CDC) suggests just over seventy percent of American adults are overweight,...
July 11, 2023 09:58 ET | Source: Spherix Global Insights

Pfizer’s Litfulo Poised to Follow Similar Trajectory as Eli Lilly/Incyte’s Olumiant for the Treatment of Severe Alopecia Areata

Exton, Pennsylvania, July 11, 2023 (GLOBE NEWSWIRE) -- In June 2022, Eli Lilly and Incyte’s Olumiant became the first and only approved advanced systemic treatment for adults with severe alopecia...